Standalone Audited Financial Results For Quarter And Year Ended March 31, 2026 and reappointment of P Vishnu Adithan as Internal Auditor of the Company
LOTUSEYE · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 0.7 pts less than Nifty Microcap 250 and 0.8 pts less than its Hospital peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
Lotus Eye Hospital reported standalone audited FY2026 results with total income of Rs 5,489.03 lakhs, up 7.9% from Rs 5,086.38 lakhs in FY2025. Revenue from operations grew 8.4% year-on-year to Rs 5,371.41 lakhs. Net profit after tax stood at Rs 73.93 lakhs, a 25.4% increase from Rs 58.97 lakhs in the prior year. The company posted a Q4 loss of Rs 37.51 lakhs, dragged down by higher service and employee costs in the quarter. Statutory auditors issued an unmodified (clean) opinion with no qualifications. The Board also reappointed P Vishnu Adithan as Internal Auditor for FY2026-27. Total assets grew to Rs 8,259.74 lakhs from Rs 6,957.37 lakhs, primarily due to a significant increase in property, plant and equipment (Rs 5,918.30 lakhs vs Rs 4,874.18 lakhs).
The 25.4% PAT growth is a positive signal for shareholders, though the EBITDA margin compression (from ~14.4% to ~9.4%) and heavy capex spending (Rs 1,295 lakhs in investing activities) raise concerns about profitability sustainability. The clean audit opinion removes any qualification-related risk.